39,655 Shares in Gossamer Bio, Inc. (NASDAQ:GOSS) Purchased by US Bancorp DE

US Bancorp DE bought a new stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 39,655 shares of the company’s stock, valued at approximately $39,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GOSS. NEA Management Company LLC grew its position in shares of Gossamer Bio by 14.2% in the second quarter. NEA Management Company LLC now owns 18,093,034 shares of the company’s stock valued at $16,300,000 after purchasing an additional 2,255,025 shares during the last quarter. Vanguard Group Inc. grew its holdings in Gossamer Bio by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 11,763,784 shares of the company’s stock valued at $13,881,000 after buying an additional 128,150 shares during the last quarter. Acadian Asset Management LLC increased its position in Gossamer Bio by 31.3% during the second quarter. Acadian Asset Management LLC now owns 3,592,765 shares of the company’s stock worth $3,235,000 after buying an additional 856,380 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Gossamer Bio by 170.8% in the second quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock worth $3,002,000 after acquiring an additional 2,103,766 shares during the last quarter. Finally, Monaco Asset Management SAM lifted its position in shares of Gossamer Bio by 390.3% in the second quarter. Monaco Asset Management SAM now owns 2,726,104 shares of the company’s stock valued at $2,456,000 after acquiring an additional 2,170,104 shares in the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Stock Performance

NASDAQ GOSS opened at $0.72 on Tuesday. The business’s 50-day moving average price is $0.93 and its 200 day moving average price is $0.87. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. Gossamer Bio, Inc. has a twelve month low of $0.50 and a twelve month high of $1.60. The company has a market capitalization of $163.17 million, a PE ratio of -2.25 and a beta of 1.96.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. The company had revenue of $9.48 million for the quarter, compared to analysts’ expectations of $4.52 million. On average, research analysts predict that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on GOSS shares. Wedbush reiterated an “outperform” rating and set a $4.00 price objective on shares of Gossamer Bio in a research report on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Gossamer Bio in a report on Monday, November 11th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $9.20.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.